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Summary Substance P (SP) and neurokinin A (NKA), which exert bronchoconstrictor effects on human airways, are 
known to interact with inflammatory and immune cells, including monocyte macrophages. We have evaluated the 
effects of SP, NKA and the NK 2 selective agonist [I~-AlaS]-NKA(4-10) on alveolar macrophages (AM) isolated from 4 
healthy smokers and 4 non-smoker active pulmonary sarcoid patients. An accumulation of activated mononuclear 
phagocytes, as well as elevated angiotensin-converting enzyme (ACE) activity, has been evidenced in both clinical 
conditions. The phenotype of AMs in the studied subjects was characterized by an elevated expression of CD68+, 
HLA-DR+ and CD14+, CD14+ being significantly less in sarcoidosis as compared to smokers. SP, NKA and the NK 2 
selective agonist evoked superoxide anion (02-) production in AMs obtained from sarcoid patients or healthy smokers. 
While SP acted in a non-dose-dependent manner in both conditions, NKA and [I3-AlaS]-NKA(4-10) evoked a dose- 
dependent respiratory burst (EDs0 = 0.25 and 0.26 riM, respectively) in smokers, but not in sarcoidosis. The more 
marked phenotypical expression correlated well with the ability of NK 2 receptors to activate AMs in smoker subjects. 
INTRODUCTION 
Pulmonary sarcoidosis i  a multisystemic granulomatous 
disease of unknown etiology mainly affecting lung inter- 
stitium, characterized by the presence of multiple non- 
caseating granulomas in affected tissues? In this disease 
the preeminent immunological bnormality is an accu- 
mulation of activated CD4+ T lymphocytes atthe site of 
disease activity, which in the respiratory tract is repre- 
sented by a CD4+ lymphocytic alveolitis) A central role 
in both the recruitment and activation of CD4+ 
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lymphocytes within alveolar spaces is played by alveolar 
macrophages (AMs)? These cells, derived from circulat- 
ing monocyte¢ and accumulated within alveolar struc- 
tures during sarcoid alveolitis, show morphological, 
phenotypical nd functional characteristics of mature, 
highly differentiated 
and activated mononuclear phagocytes, 3 producing 
and releasing increased amounts of proinflammatory 
cytokines and oxygen-derived free radicals as immune 
response to unknown antigen(s)? Another condition in 
which an accumulation f activated mononuclear phago- 
cytes is usually observed is the macrophage alveolitis 
occurring in smoker subiects; in smokers a morpho- 
phenotypical nd functional pattern of AMs as the one 
observed in sarcoidosis has been described to be associ- 
ated with a not significantly increased number of AMs? 
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AMs are a heterogeneous cell population, differing in 
morphological, phenotypical nd functional characteris- 
tics in both healthy subjects and patients. 3-5 By employ- 
ing bronchoalveolar l vage (BAL), discontinous gradient 
centrifugation or monoclonal antibodies, some interest- 
ing relationships between AM structure, phenotype and 
function have been evidenced in bronchial asthma as 
well as in pulmonary tuberculosis: large, hypodense cells 
are activated, mature monuclear phagocytes showing an 
increased oxidative burst. 6-a Unfortunately these findings 
are not homogeneously present in all evaluated condi- 
tions; for example, Sandron et al~ failed to demonstrate 
any relationship between different AM subpopulations 
and their activity in both healthy subjects and patients 
with active pulmonary sarcoidosis. According to Hinman 
et al, ~° AMs from sarcoid patients or smokers share 
another common feature: both present an elevated 
angiotensin-converting e zyme (ACE) activity. However, 
this functional characteristic of AMs was also not 
observed by Gupta et a111 who failed to demonstrate an 
increase of ACE levels in BAL fluid from smokers. ACE, 
together with neutral endopeptidase and aminopepti- 
dase, is able to degrade tachykinins, a family of peptides 
with the same C-terminal sequence Phe-X-Gly-Leu-Met- 
NH2. I2 Three types of tachykinin receptors, namely NK1, 
NK 2 and NK3, are described to preferentially interact with 
substance P (SP), neurokinin A (NKA) and neurokinin B 
(NKB), respectively. ~2 SP and NKA, which are co-localized 
to sensory afferent C-fibers and released locally by an 
axon reflex, are deeply involved in lung pathophysiol- 
ogyY Relationships between these nervous fibers and 
tachykinin levels within lung tissues are underlined by 
the lack of tachykinin immunoreactive n rves in trans- 
planted lungs and by the reduction of SP levels in BAL 
fluid from transplanted lungs. 13,~4 Besides inducing bron- 
choconstriction i vivo and in vitro, enhancing plasma 
exudation and mucous ecretion, tachykinins exert mod- 
ulatory effects on cells involved in inflammatory and 
immune processesY SP degranulates mast cells, stimu- 
lates both DNA and protein synthesis from human T 
lymphocytes and exerts priming effects on neu- 
trophilsY ,~6 Lotz et al~z demonstrated that NKA and SP 
(the former being more potent) evoke the release of pro- 
inflammatory cytokines from human circulating mono- 
cytes. Brunelleschi et all8 reported that tachykinins 
activate guinea-pig AMs: the order of potency (NKA > SP 
> NKB) and the ability of an NK a receptor agonist to 
evoke superoxide anion production and eicosanoid 
release from these ceils indicate that guinea-pig AMs 
present achykinin NK 2 receptors mainly. ~a,~9 Therefore, 
we decided to evaluate whether or not SP, NKA and a 
selective NK 2 receptor agonist were able to induce super- 
oxide anion production from AMs of sarcoid patients or 
human smokers. 
MATERIALS AND METHODS 
Study population 
Four patients, 3 males and 1 female, aged between 28 
and 46 years, non-smokers, with newly diagnosed 
pulmonary sarcoidosis, were studied. Diagnosis was 
done on the basis of clinical, laboratory and chest X-ray 
data, and confirmed by histological findings on speci- 
mens from transbronchial lung biopsies during bron- 
choscopy after bronchoalveolar l vage was done in the 
lobe. Histological analysis of biopsy specimens showed 
the presence of typical sarcoid (non-caseating granu- 
loma with giant cells and no necrosis) in all samples. All 
sarcoid patients had an active disease, as defined by 
employing standard criteria: clinical (fever, chest pain, 
dyspnoea on exertion, cough), scintigrafic (positivity of 
~Tgallium lung scan), biological (elevated serum 
angiotensin-converting e zyme [sACE] levels) and lung 
functional (at least reduced resting carbon monoxide 
diffusion, DICO) tests. None of the patients had a med- 
ical history of asthma, and pulmonary function tests 
excluded actual obstruction. No patients had received 
steroids or other therapy at the time of the study. The 
other group was composed by 4 healthy smoker sub- 
jects (3 males and 1 female) aged between 18 and 63 
years. This study and the research protocol were 
approved by the Ethical Committee of the University of 
Turin. 
Bronchoalveolar lavage and cell preparation 
Bronchoalveolar lavage (BAL) was performed as previ- 
ously described. 2° Briefly, informed consent was obtained 
from each subject; after pretreatment with parenteral 
atropine sulphate (0.5 rag), airways were anesthetized 
with 20/0 lidocaine. A fiberoptic bronchoscope (Olympus 
BF-1TIO) was advanced and wedged into the middle lobe 
under direct visualization. Lavage was carried out with 
200 ml of prewarmed (37°C) sterile saline solution in ten 
20-ml aliquots with immediate gentle vacuum (syringe) 
aspiration after each injection. The total amount of 
recovered fluid was measured (always >600/0 of injected 
saline); the first recovered aliquot was separately exam- 
ined for cytological and bacteriological studies and the 
other ones pooled. Immediately after lavage the fluid was 
filtered through two layers of sterile surgical gauze. Cells 
were separated from the lavage fluid by centrifugation i  
a refrigerated centrifuge (4°C, 20 rain, 900 rpm) and 
washed in phosphate-buffered salt solution (PBS; Serva). 
Total cell count and viability evaluation (Trypan blue dye 
exclusion test; always >95%) were performed on a 
Burker haemocytometer, differential cell count was done 
on Diff-Quick (Don Baxter) stained cytospin smears, 
counting at least 400 cells. 
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Immediately before BAL premedication, peripheral 
blood samples were obtained from each studied subject 
by venipuncture; 10-ml vacuum sterile tubes 
(Vacutainer, Becton-Dickinson) were employed. The sam- 
ples were allowed to clot; serum was gently removed 
after centrifugation (5 min, 2000 rpm) and stored at 
-80°C until utilized for sACE level determinations. 
Phenotypical studies of alveolar cells 
Alveolar lymphocytes 
The whole cellular BAL pellet was washed twice in PBS, 
resuspended in sterile culture medium (RPMI 1640) and 
placed in flat bottom, multiwell polystyrene plates. After 
1 h incubation at 37°C in humidified 5% CO 2 atmos- 
phere, non-adherent cells (mainly lymphocytes) were 
gently collected. Phenotypical nalysis of these cells was 
carried out, after two additional PBS washings, by 
employing a panel of commercial available monoclonal 
antibodies (Table 1) and flow cytometry (FACSCAN, 
Becton-Dickinson). Standard staining procedures 21 and 
single or two-colour analysis with FACSCAN software 
were used (at least 5000 events for each sample were 
assumed and cells evaluated). Lymphocyte gates were 
obtained by using linear forward angle light scatter, the 
lymphocyte gates were validated by employing CD45- 
fluorescein-conjugated (panleucocyte) and CD14phyco- 
erythrin-conjugated (monocyte) monoclonal ntibodies. 21 
The lymphocyte population was defined as CD45 b"g"t 
CD14nega*i~°; more than 95% of all lymphocytes in each 
sample were contained within the boundaries of the lym- 
phocyte light-scatter gate. 
Alveolar macrophages 
Adherent AMs were obtained after 1 h incubation at 
37°C in humidified 5% CO 2 atmosphere and used for 
functional studies (see below). Adherent BAL cells, after 
removal of non-adherent ones by gentle washing with 
prewarmed sterile PBS, were detatched by scraping 
with a plastic scraper. After three washings with sterile 
PBS, the removed adherent cells were resuspended at
the final concentration of 1 x 105 cells/ml in sterile PBS; 
thereafter, cytocentrifuge preparations were prepared 
from this cell suspension i  a cytocentrifuge (Cytospin, 
Shandon, UK) at 500 rpm for 10 min. Phenotypical 
analysis of alveolar macrophages was carried out on 
these cytocentrifuge slides by employing leukocyte- 
specific monoclonal antibodies (MoAb) as listed in 
Table 1. As controls non-specific mouse IgG1, IgG2 and 
IgM (Dako) were used; staining with these negative 
controls was always negative. Briefly, cytocentrifuge 
preparations were fixed in ethanol (Merck) for 5 min 
and washed with PBS (one smear was employed for 
each MoAb) and incubated with horse non-immune 
anti-mouse serum (Dako) for 20 min. After washing 
three times with PBS, the slides were incubated for 1 h 
with the appropriate MoAb at the dilution suggested by 
the manufacturer. After washing three times with PBS, 
the slides were incubated for 1 with a directly biotiny- 
lated second antibody at 1/200 dilution in PBS (Dako). 
After three washings with PBS, 1 h incubation with avi- 
dine-biotin complex conjugated with alkaline phos- 
phatase (Dako) was performed; at last, after a washing 
with Tris-HC1 (0.1 M, pH 8.2), fast red naphthol phos- 
phate (with levamisole 1.25 mM) (Dako) was added 
(37°C, 5 rain) to develop a brillant red staining of posi- 
tive cells (this colour was chosen to avoid possible 
interferences with brownish or black cytoplasmic nclu- 
sions of alveolar macrophages). Positive cells were 
counted by evaluating at least 200 cells. Selected slides 
were stained for either acid phosphatase or non-spe- 
cific esterase (alpha-naphtyl esterase). Counterstaining 
Table 1 Monoclonal antibodies employed in the phenotypical study of mononuclear alveolar cells 
CD Commercial Cell/function 
CD3 Anti-LEU4a (BD) 
CD4 Anti-LEU3a (BD) 
CD8 Anti-LEU2a (BD) 
- Anti-HLA-DR (BD) 
CD25 Anti-lL2 Receptor (BD) 
CD68 Anti CD68 (Dako) 
CD14 Anti-LEUm3 (BD) 
CD45 Anti-human Leukocyte (BD) 
T-lymphocytes 
Helper/inducer T-lymphocytes 
Suppressor/cytotoxic T-lymphocytes 
II Class MHC, activated T-lymphocytes and macrophages 
IL-2 receptor, a chain; activated, proliferating T-lymphocytes 
Oxidative burst-related antigen 
LPS receptor 
Pan leukocyte 
Cluster designation (CD; when available), commercial definition and source, and characteristics ofcells identified by monoclonal 
antibodies are contained in this table. BD: Becton Dickinson; Dako: Dako Patts. 
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was performed with hematoxylin (Merck). Finally, the 
slides were dehydrated in ethanol and embedded in 
mounting medium (Entellan Merck). The slides were 
evaluated independently by two investigators and at 
least 200 cells were counted for each marker on each 
slide. 
Functional studies of alveolar macrophages: 
superoxide anion production 
Adherent AMs (106/dish) were washed twice with PBS 
and then incubated in sterile culture medium (MEM 
without phenol red). Alveolar macrophages were pre- 
treated for 15 rain at 37°C with a cocktail of inhibitors: 
captopril, thiorphan and bestatin, all at 1 gM. This con- 
centration was demonstrated to block tachykinin- 
degrading enzymesY ,18 Cells were then challenged with 
increasing concentrations of substance P (SP), neu- 
rokinin A (NKA) and [~-Ala~]-NKA(4-10) (a selective NK 2 
receptor agonist) for 30 min. The effects of tachykinins 
were compared with those evoked by the bacterial pep- 
tide N-formylmethionyl-leucyl-phenylalanine (FMLP). 
Superoxide anion (O2~ production was evaluated by 
the superoxide dismutase-inhibitable cytochrome C 
reduction, the absorbance changes being recorded at 550 
nm in a Perkin Elmer spectrophotometer. 02- production 
was expressed as nmol cytochrome C reduced/10 ~ 
AMs/30 min, using an extinction coefficient of 21.1 
mM. 1~ To avoid interference with spectrophotometrical 
recordings of 02- production, monolayers were incubated 
with MEM without phenol red. 
Experiments were performed in triplicate and control 
values (e.g. basal 02 - production) were subtracted from 
all determinations. All results are expressed as means + 
SEM. Statistical analysis was performed by using 
Student's ttest. 
BALf concentration procedure 
Each sample of BAL, after centrifugation a d separation of 
the cellular pellet, was concentrated by employing a 
selective membrane for uhrafiltration with an adequate 
molecular weight cut-off (10 000 Da) and with low inter- 
action with proteins (Amicon YM 1 O) in a magnetic-stirred 
positive pressure (N) cell (Amicon Grace, Italy). 
ACE level measurements in bronchoalveolar lavage 
fluid (lACE) and in serum (sACE) 
Levels of ACE in both serum and 50-fold concentrated BALf 
were determined by commercially available (ACEcolor, 
Fuiirebio Inc, Tokyo, Japan) colorimetric method, employ- 
ing p-hydroxybenzoyl-glycyl-L-histidyl-Meucine as sub- 
strate for ACE activity determination. The absorbance was 
read at 505 nm, using distilled water as control. The cut-off 
value was 21.4 mU/ml for sACE and 30.7 mU/ml for LACE, 
respectively (mean values of healthy controls + 2 SD of the 
mean). 
Chemicals 
The compounds used and their sources were as follows: 
SP, NKA, [[~-AlaS]-NKA(4-10), bestatin (Peninsula); thior- 
phan, captoprfl, superoxide dismutase, cytochrome C 
type VI, Tris-HC1, FMLP (Sigma); PBS and RPMI 1640 
(Serva); MEM without phenol red (Gibco). 
RESULTS 
Phenotypical studies of alveolar cells 
All samples from studied subjects howed no growth of 
Gram+ve or Gram-ve bacteria, mycobacteria or fungi 
(data not shown). Cytological examination of all BAL 
samples showed no presence of atypical cells 
(Papanicolau staining). More than 95% of recovered cells 
were viable in all studied samples. Total and differential 
cell count in patients with pulmonary sarcoidosis and in 
healthy smokers are shown in Table 2: in both healthy 
smokers and sarcoid patients an increase of total cell 
count was observed. Alveolar lymphocytosis was higher 
in the sarcoidosis group, whereas a marked increase of 
alveolar macrophages was observed in smokers (Table 2). 
Moreover, a mild increase of alveolar neutrophil percent- 
age was observed only in smokers (Table 2). 
Alveolar lymphocyte subsets and activation antigen 
expression on alveolar lymphocytes in both healthy smok- 
ers and sarcoid patients are shown in Table 3: in smoker 
subjects a normal CD4/CD8 ratio was observed, while in 
sarcoid patients the hallmark of an increased percentage 
of CD4+ cells and a significantly elevated CD4/CD8 ratio 
were found. As expected, the activation marker expression 
was particularly evident in the sarcoidosis group as evi- 
denced by the results obtained by evaluating CD3+/HLA- 
DR co-expression and CD4+/CD25+ co-expression (Table 
3). More than 90% of cells on cytospin slides were acid- 
phosphatase positive phagocytes reacting with non- 
specific esterase. 
The phenotype of AMs in studied subjects is reported in 
Table 4: the great majority of AMs (96.25 +_ 2.3%) in smok- 
ers were CD68+ and a high percentage (83.75 _+ 2.3% and 
6Z5 + Z7%, respectively) ofAMs also expressed CD14 and 
HLA-DR. In pulmonary sarcoid patients, the percentage of
AMs expressing CD68+, although elevated (82 + 50/0), was 
significantly less (P (0.05)  than the one observed in 
smokers, as was the percentage ofAMs expressing CD14+ 
(25.2 + 1.8%; P (0.001) (Table 4). Levels of ACE in both 
serum and BALl are recorded in Table 5: all sarcoidosis 
patients howed sACE and lACE levels significantly higher 
(P(0.001) than smoker subjects. 
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Table 2 Total and differential cell count in BALf of studied subjects 
Patients Total cell AM(%) LY(%) PMN(%) EOS(%) 
(age; sex) (x 10 ~) 
Smokers 
1 (54; M) 2.01 93 6 1 0 
2 (63; M) 1.45 90 7 3 0 
3 (50; M) 5.20 90 5 5 0 
4 (18; F) 5.22 93 3 4 0 
Means + SEM 3.47_+1 91.5 -+ 0.8 5 _+ 1 3.25 _+ 0.8 0 
Sarcoidosis 
5 (43; M) 1.61 64 35 0 1 
6 (46; M) 2.89 92 6 2 0 
7 (29; M) 4,54 59 40 1 0 
8 (28; F) 2.37 70 29 1 0 
Means + SEM 2.85 _+ 0.6 71,2 _+ 7.2* 27.5 + 7,5" 1 _+ 0.4* 0.25 + 0.25 
Data are given as total cell number/ml BAL x 10' and as percentage of total cell population (differential). AM = alveolar 
macrophages, LY = alveolar lymphocytes; PMN = alveolar neutrophils; EOS = alveolar eosinophils. *P < 0.05 vs 
smokers, 
Superoxide anion production from 
alveolar macrophages 
Basal values (02- production from unstimulated cells) in 
smoker subjects and sarcoid patients were 12.04 + 0.4 
(n = 4) and 4.02 + 0.86 (n = 4; P(0.01) nmol cytochrome 
C reduced/106 AMs/30 min, respectively. These values 
were subtracted from those observed after tachykinin or 
FMLP challenge to obtain the net 02- production. 
The bacterial peptide FMLP, used at 10 -z M (a near 
maximal concentration), produced 4.12 +_ 0.4 (n = 4) and 
Z32 +_ 1.9 (n = 4) nmol cytochrome C reduced/106 
AMs/30 min in smoker subjects and sarcoid patients, 
respectively. 
When challenged with SP, NKA or the selective NK 2 
agonist [[~-AlaS]-NKA(4-10), AMs from smokers pre- 
sented a significant 02- production (Fig. 1). However, 
while SP (10 -1° to 10-6M) acted with a non-dose-depen- 
dent pattern, NKA (10 -12 to 10-~M) displayed a dose- 
dependent effect, maximal activation (9.6 +_ 2.6 nmol 
cytochrome C reduced/106 AMs/30 re_in; n = 4) being 
achieved at 10-TM and EDs0 value being 0.25 nM (Fig. 1). 
The NK 2 selective agonist evoked a dose-dependent 02- 
Table 3 Alveolar lymphocyte subsets and activation antigen expression in smoker subjects and in non-smoker active pulmonary sarcoidosis 
Patients CD3+ CD4+ CD8+ CD4+/CD8+ CD3+/HLADR+ CD4+/CD25+ 
ratio co-expression co-expression 
Smokers 
1 95.0 72.1 20.7 3.43 14.5 1.5 
2 92.8 48.6 46.4 1.04 7.5 0.3 
3 93.8 56.3 36.8 1.52 26.3 1.0 
4 95.0 45,9 44.3 1.03 6.8 1.2 
Means + SEM 94.15+0.5 55 .5+5 37.05+5 1.75_+0.5 13.8_+4.5 1 +0.25 
Sarcoidosis 
5 89.0 62.0 14.6 4.25 15.5 2.9 
6 96.4 73.4 18.3 4.01 36.5 4.4 
7 96.1 81.9 11.6 7.06 27.4 3.6 
8 97.1 88.0 7.6 11.05 41.7 3.3 
Means + SEM 94.8_+1.9 76.3+ 5,6" 13+2.2"  6 .7+1.7"  30.3_+5,7* 3,5_+0.3** 
Positive cells are expressed as percentage of total alveolar lymphocytes. * P < 0.05 vs smokers; ** P < 0.01 vs smokers. 
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Table 4 CD68, HLA-DR and CD14 expression on alveolar macrophages in smoker subjects 
and in non-smoker active pulmonary sarcoidosis 
Patients CD68 + HLA-DR + CD14 + 
Smokers 
1 100 80 65 
2 90 90 90 
3 100 85 55 
4 95 80 60 
Means ± SEM 96.2 ± 2.3 83.7 ± 2.3 67.5 ± 7 
Sarcoidosis 
5 1.61 64 22 
6 2.89 92 30 
7 4.54 59 26 
8 2.37 70 23 
Means ± SEM 82 ± 5 * 94 ± 2.3 * 25.2 ± 2 ** 
Positive cells are expressed as percentage of total alveolar macrophages. * P < 0.05 vs 
smokers; ** P < 0.01 vs smokers. 
production, with maximal effects at lO-aM and an EDso = 
0.26 nM (Fig. 1). 
As depicted in Figure 2, SP, NKA and [[3-AlaS] - 
NKA(4-10) induced 02- production in a non-dose- 
dependent fashion in AMs from sarcoid patients. The 
amount of 02- production evoked by NK 2 receptor 
stimulation was less (P < 0.05) than the ones observed 
in smokers, while SP exerted similar effects (Fig. 2). 
When the respiratory burst was evaluated as a percent 
of control values, an interesting feature emerged. In 
smoker subjects, NKA-evoked 02- production ranged 
between 110 and 180% of the control value, at 10-'2M and 
10-TM, respectively, while in sarcoid patients NKA-evoked 
02 production increased about 2-fold for all the concen- 
trations evaluated (data not shown). SP-evoked O 2- pro- 
duction increased to about 140-150% of the control value 
in smokers and 230-240% of the control value in sarcoid 
patients for all the concentrations evaluated (data not 
shown). [[~-AlaS]-NKA(4-10) induced a higher respiratory 
burst ranging from 120% of the control value at 10-"M to 
180% at 10-6M in smokers and about 220-240% of the 
control value in sarcoid patients (data not shown). FMLP- 
evoked 02 - production was about 130% of the control 
value in smokers and 280% in sarcoid patients. 
DISCUSSION 
Table 5 ACE levels in BAL fluid (lACE) and serum (sACE) 
Patient sACE lACE 
Smokers 
1 4.3 8.1 
2 10.2 14.5 
3 6,5 11.6 
4 8.1 12 
Means + SEM 7.25 + 1.2 11.52 + 1.3 
Sarcoidosis 
5 28.4 58.1 
6 32.5 64.2 
7 41.1 71.4 
8 35.4 59.6 
Means + SEM 34.3 + 2.7 * 63.3 + 2.9* 
Data are expressed as mU/ml serum and mU/ml unconcentrated 
BAL fluid. *P< 0.001 vs smokers. 
This study demonstrates that mammalian tachykinins SP 
and NKA, as well as the selective NK 2 agonist 
[[3-AIa~]NKA(4-10), induce 02- production in AMs 
obtained from sarcoid patients or healthy smokers. As far 
as SP (which represents the major endogenous agonist 
for the tachykinin NK 1 receptor) is concerned, 02- pro- 
duction increased to more than 230% of the control 
value in sarcoid patients, while in smokers the respira- 
tory burst was about 150% of the control value. 
However, while SP acted dose-independently in both 
conditions, NKA and the NI~ selective agonist evoked a 
dose-dependent respiratory burst in smokers, but not in 
sarcoid patients. The functional study was performed in 
the presence of a cocktail of inhibitors (thiorphan, capto- 
pril and bestatin) of tachylanin-degrading e zymes (neu- 
tral endopeptidase [NEP], ACE and aminopeptidase, 
respectively), since it is known from the literature that 
the activity of NEP and ACE represents an important fac- 
tor in determining the effects of tachykinins. 12,22 
Moreover, the activity of both degrading enzymes could 
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Fig. 1 Effect of neurokinin A (NKA), substance P (SP) and the NK 2 selective agonist [~-AlaS]-NKA(4-10) on superoxide anion production in 
alveolar macrophages obtained from healthy smokers. Cells were pretreated with a cocktail of inhibitors (see Methods) and then challenged 
with tachykinins. Means + SEM; n = 4. 
be modified in the clinical conditions we evaluated. 
Hinman et al 1° reported that human AMs "normally' con- 
tain ACE activity and that this activity increased five 
times in AMs obtained by the three sarcoid patients they 
evaluated, while a two-fold increase was detected in AMs 
from 1 1 smokers. Dusser et a123 demonstrated that, in the 
guinea-pig, cigarette smoke enhanced SP-induced bron- 
choconstriction by inactivating airway NER 
SP and NKA are present in human lung and have been 
detected and measured in BAt,, as well as NEP and ACE: 22 
so, we thought o evaluate the effects of tachykinins on 
AMs in the presence of inhibitors. To our knowledge, 
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Fig. 2 Effect of neurokinin A (NKA), substance P (SP) and the NK 2 selective agonist [I~-AlaS]-NKA(4-10) on superoxide anion production in 
alveolar macrophages obtained from sarcoid patients. Cells were pretreated with a cocktail of inhibitors (see Methods) and then challenged 
with tachykinins. Means + SEM; n = 4. 
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only Pujol et a124 have been interested in evaluating 
tachykinin effects on human AMs, while many investiga- 
tors have determined tachykinin effects in guinea-pig 
AMs ~8'~'2~'26 or human monocytes, lz2z28 Pujol et al 2~ evalu- 
ated the ability of SP, at concentrations (10-TM to 10-4M) 
higher than the ones we have used in this study, to 
stimulate TXB 2 release in AMs from six normal subjects 
and seven asthmatic patients, but they found a signifi- 
cant TXB 2 release only in one asthmatic patient and no 
stimulation in normal subjects. We have not evaluated 
control healthy subjects, as we were more interested, in 
this first phase of our work, to look at possible tachykinin 
effects in pathological conditions. The results obtained 
by measuring spontaneous O; production, which is sig- 
nificantly enhanced in smokers' AMs as compared to sar- 
coid patients' AMs, are in good agreement with 
published ata. 8, a~,~° 
The ability of tachykinins to stimulate AMs in active 
pulmonary sarcoidosis and tobacco smoke related alve- 
olitis reflects two different clinical conditions, both char- 
acterized by an increased number of activated AMs. 
Otherwise, the observed ifferences of the phenotypical 
pattern of AMs, showing a more marked expression of 
CD68, HLA-DR and CD14, respectively, related to the 
presence of mononuclear phagocytes involved in the 
oxidative burst (CD68), ~ in antigen presentation (HLA- 
DR) ~2 and in cytokine production by LPS (lipopolysaccha- 
ride) receptor (CD14) 33 that we found in smoker group vs 
sarcoidosis patients, correlated well with the ability of 
tachykinins (and especially NK 2 receptor stimulation) to 
activate AMs in our patients. 
Recently, Tomaki et al, ~ in a study designed to investi- 
gate the reasons for the development of cough in a 
small percentage (10-15%) only of patients treated with 
ACE inhibitors, suggested that the effects of SP could be 
related to a receptor-mediated priming of the airways, 
since cough-positive patients receiving a repeated ose 
of enalapril after discontinuation of the therapy, pre- 
sented the symptoms again, while SP levels in induced 
sputum were similar to the ones measured whilst off the 
medication24 In patients with chronic bronchitis, the 
increased levels of SP in induced sputum have been 
claimed to activate inflammatory mechanisms leading 
to local airway damage2 ~ In sarcoidosis, a disease in 
which an increase in both sACE and 1ACE levels has 
been described as a consequence of the enhanced secre- 
tory activity of AMs, ~6,~ a particular local (alveolar) con- 
dition may develop: high concentrations of tachykinin 
degrading enzyme (e.g. ACE) could reduce local levels 
of SP, whereas the same mechanism could not be effec- 
tive in smokers. Consequently, although our study 
refers to a small number of patients only, 
we could hypothesize that different responses to 
tachykinin stimulation of AMs obtained from healthy 
smokers (showing lower levels of 1ACE as compared to 
sarcoid patients) may be related to a different priming of 
AMs, largely mediated by the different levels of ACE 
activity within the alveolar microenvironment. The acti- 
vation pattern of AMs following tachykinin stimulation 
we observed in smokers is in keeping with the observa- 
tion of enhanced SP content in sputum from chronic 
bronchitis patients. The increase of tachykinin-evoked 
AM oxidative burst we observed in smokers could be 
considered to represent he result of an AM priming 
(which is highly possible in patients without a signifi- 
cant increase of alveolar ACE levels). In keeping with 
this hypothesis i the observation that the prevalence of 
pulmonary sarcoidosis is reduced in smoking popula- 
tionY In addition, among patients with pulmonary sar- 
coidosis, the smoker ones show higher sACE levels and 
lower CD4/CD8 ratio in BAL, related to an increase in 
CD8+ lymphocytesY 
In conclusion, tachykinins may represent another 
group of mediators capable of modulating lung damage 
in different conditions by their ability to activate AMs; 
the presence of varied levels of ACE activity in alveolar 
spaces observed in smokers and in active pulmonary sar- 
coidosis seems to influence this activation pathway. 
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